Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size to Surpass US$ 31.4 BN By 2030

According to latest report study, the global Chronic Obstructive Pulmonary Disease (COPD) Treatment market size was estimated at USD 19.11 billion in 2021 and is expected to surpass around USD 31.4 billion by 2030 and poised to grow at a compound annual growth rate (CAGR) of 5.9% during the forecast period 2022 to 2030. 

Request Free Sample of This Report@ https://www.novaoneadvisor.com/report/sample/7025

Chronic obstructive pulmonary disease is a group of conditions affecting lungs that leads to difficulty in breathing. Chronic bronchitis and emphysema are two major types of COPD. Breathlessness is a major characteristic of COPD. In case of emphysema, the alveoli (tiny air sacs) in the lungs are damaged. The walls of the alveoli are stretched, making the lungs bigger. This results in difficulty in the movement of air. In chronic bronchitis, bronchial airways (breathing tubes) inside the lungs are inflamed.

High prevalence of COPD across the globe and rich pipeline of drugs for COPD treatment are likely to drive the global market during the forecast period. Increase in geriatric population and rise in unhealthy lifestyle among various age groups are also projected to propel the chronic obstructive pulmonary disease (COPD) treatment market in the near future.

Report Scope of the Chronic Obstructive Pulmonary Disease (COPD) Treatment  Market

Report Coverage

Details

Market Size

USD xx Billion by 2030

Growth Rate

CAGR of xx% from 2022 to 2030

Largest Market

North America

Fastest Growing Market

Asia Pacific

Base Year

2021

Forecast Period

2022 to 2030

Segments Covered

 Drug Class, Type, Distribution Channel, And Geography

 

Full Report is Ready | Quick Buy This Premium Report from Here@  https://www.novaoneadvisor.com/report/checkout/7025

Rise in Tobacco Smoking to Propel Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market

Chronic obstructive pulmonary disease (COPD) is a major health concern affecting a large number of people across the globe. The disease burden is rising, thereby increasing the need for COPD management.

Tobacco smoking could lead to COPD. The number of adults addicted to smoking has been increasing across the globe. Other risk factors include occupation and indoor air pollution. According to the WHO, the primary cause of COPD is exposure to tobacco smoke (either active or passive smoking).

According to the World Health Organization (WHO), chronic obstructive pulmonary disease (COPD) is the third leading cause of death globally, accounting for 3.23 million deaths in 2019. Nearly 90% of COPD deaths in those under 70 years of age occur in low- and middle-income countries (LMIC).

According to a report by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) published in 2022, the prevalence and burden of COPD are projected to increase in the near future due to continued exposure to COPD risk factors and aging of population across the globe. This is anticipated to augment the chronic obstructive pulmonary disease treatment market in the near future.

Increase in Adoption of Combination Therapy to Drive Market

Combination therapy includes LAMA-ICS, LABA-ICS, triple therapy, and other combination drugs. Adoption of combination therapy is increasing, as it is more effective than the separate use of bronchodilator and corticosteroid. Increase in number of patients being successfully treated with combination therapy, who were not showing signs of recovery with bronchodilators or corticosteroids treatments, is expected to boost the global chronic obstructive pulmonary disease treatment market. Combination therapy is more effective than monotherapy for improving chronic obstructive pulmonary disease symptoms and quality of life.

Growth in Success Rate of COPD Treatment and Recent Regulatory Approvals to Augment Combination Therapy Segment

In terms of drug class, the combination therapy segment held major share of around 50% of the global market in 2021. It is likely to dominate the global market during the forecast period, owing to the increase in efficacy of combination therapy in COPD treatment.

Rise in success rate of combination therapy in COPD treatment and recent regulatory approvals have augmented the adoption of combination therapy. This is projected to drive the segment during the forecast period.

Rise in Number of COPD Therapeutics Dispensed to Boost Retail Pharmacies Segment

Based on distribution channel, the retail pharmacies segment is anticipated to account for major share of the global chronic obstructive pulmonary disease treatment market during the forecast period.

The segment is expected to grow at a rapid pace during the forecast period, owing to the increase in number of COPD therapeutics dispensed through retail pharmacies and rise in number of retail pharmacies in developing countries.

Regional Outlook of Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market

North America accounted for the largest share of around 40% of the global chronic obstructive pulmonary disease (COPD) treatment market in 2021. The market in the region is projected to grow at a CAGR of 4.3% from 2022 to 2031. This can be ascribed to the highly structured health care industry and availability of well-defined reimbursement policies from private and public health insurance firms in the region. Additionally, extensive research & development to provide advanced and efficient products and presence of large numbers of players are driving the chronic obstructive pulmonary disease treatment market in North America.

Europe held the second largest share of the global market in 2021. Well-developed health care infrastructure and increase in incidence of chronic obstructive pulmonary disease are propelling the COPD treatment market in the region.

The market in Asia Pacific is expected to grow at the fastest CAGR of 4.7% during the forecast period. The region has a relatively untapped chronic obstructive pulmonary disease treatment market than developed regions. Hence, Asia Pacific offers significant opportunities to market players. High prevalence of chronic obstructive pulmonary disease, increase in geriatric population, surge in patient population, and growth of the health care industry are propelling the chronic obstructive pulmonary disease treatment market in the region.

Analysis of Key Players in Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market

The global chronic obstructive pulmonary disease (COPD) treatment market is consolidated, with the presence of a small number of key players.

Expansion of product portfolio and mergers & acquisitions are the key strategies adopted by the leading players. Key players operating in the global chronic obstructive pulmonary disease (COPD) treatment market include Almirall, AstraZeneca, Boehringer Ingelheim International GmbH, CHIESI Farmaceutici S.p.A., F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Kyowa Hakko Kirin, Mylan N.V., Novartis AG, Orion Corporation, Sanofi, Sunovion Pharmaceuticals Inc. (Sumitomo Dainippon Pharma Co., Ltd.), Teva Pharmaceutical Industries Ltd., Theravance Biopharma, and Verona Pharmaceuticals.

Key Developments in Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market

  • In January 2022, the first patient was enrolled in a phase 4 study comparing Yupelri (revefenacin) to Spiriva (tiotropium) in improving lung health in adults with severe chronic obstructive pulmonary disease (COPD). The safety of these two approved once-daily COPD maintenance treatments will be assessed as well. Yupelri is a bronchodilator, a type of medication that relaxes and widens the lung airways, making breathing easier. It was developed by Theravance Biopharma and Mylan (now part of Viatris). It is available as an inhalable solution via a nebulizer, a small machine that turns liquid into a fine mist.
  • In November 2021, AstraZeneca announced that it had sold rights to sell Tudorza, also known as Eklira, and Duaklir to the Switzerland-based pharmaceutical company Covis Pharma Group for US$ 270 Mn. These products are indicated for the treatment of chronic obstructive pulmonary disease (COPD).
  • In October 2021, Mylan Pharmaceuticals received the FDA approval for its investigational new drug application (ANDA) for Breyna (budesonide and formoterol fumarate dihydrate inhalation aerosol), the first approved generic version of AstraZeneca's Symbicort. It will be available in dosage strengths of 160 mcg/4.5 mcg and 80 mcg/4.5 mcg for patients with asthma or chronic obstructive pulmonary disease (COPD).
  • In January 2019, CHIESI Farmaceutici S.p.A. entered into an exclusive global license agreement with TiumBio, a clinical-stage private biotech company based in South Korea. TiumBio specializes in research on innovative drugs for rare diseases. The agreement is aimed at developing innovative molecules for usage in the treatment of respiratory diseases.

Some of the prominent players in the Chronic Obstructive Pulmonary Disease (COPD) Treatment  Market include:

  • Almirall
  • AstraZeneca
  • Boehringer Ingelheim International GmbH
  • CHIESI Farmaceutici S.p.A.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc
  • Kyowa Hakko Kirin
  • Mylan N.V.
  • Novartis AG
  • Orion Corporation
  • Sanofi
  • Sunovion Pharmaceuticals, Inc. (Sumitomo Dainippon Pharma Co., Ltd.)
  • Teva Pharmaceutical Industries Ltd.
  • Theravance Biopharma
  • Verona Pharmaceuticals

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2030. For this study, Nova one advisor, Inc. has segmented the global Chronic Obstructive Pulmonary Disease (COPD) Treatment  market

  • Drug Class
    • Combination Therapy
    • Bronchodilators
    • Corticosteroids
    • Phosphodiesterase Type 4 Inhibitor
    • Mucokinetics
    • Others
  • Type
    • Chronic Bronchitis
    • Emphysema
  • Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies

By Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Key Benefits for Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the global Chronic Obstructive Pulmonary Disease (COPD) Treatment industry analysis from 2022 to 2030 to identify the prevailing Chronic Obstructive Pulmonary Disease (COPD) Treatment industry opportunity.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the global Chronic Obstructive Pulmonary Disease (COPD) Treatment industry segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global Chronic Obstructive Pulmonary Disease (COPD) Treatment industry trends, key players, market segments, application areas, and market growth strategies.

Full Report is Ready | For Purchase Inquiry@ https://www.novaoneadvisor.com/report/checkout/7025

You can place an order or ask any questions, please feel free to sales@novaoneadvisor.com| +1 9197 992 333

Blog: https://www.novaoneadvisor.com/

Blog: https://www.visionresearchreports.com/

Blog: https://qyresearchmedical.com/

 

 

Back to news